Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics has launched an equity raising comprising a placement of new fully paid ordinary shares to eligible institutional, sophisticated and professional investors, alongside a non-renounceable entitlement offer of new shares to existing eligible shareholders. The offer, which is not underwritten and may be varied or withdrawn at the company’s discretion, is being managed by Morgans Corporate Limited and includes the potential placement of any shortfall shares within three months of the entitlement offer’s close, with allocations determined by Neurizon to support an informed and liquid trading market and a broad, long-term shareholder base.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a biotechnology company focused on therapeutic drug development, operating through Neurizon and its subsidiaries. The group targets investors in the Australian capital markets and is subject to ASX listing and disclosure requirements.
Average Trading Volume: 817,788
Technical Sentiment Signal: Sell
Current Market Cap: A$58.82M
For detailed information about NUZ stock, go to TipRanks’ Stock Analysis page.